T cells and macrophages. Discussion This study demonstrates complete B-cell depletion in secondary lymphoid tissues of patients with AIDs following CD19-CAR T-cell therapy combined with standard ...

Each of these mechanisms (Figure 1) contributes to the overall effectiveness of CAR-Macrophages in targeting and eliminating cancer cells, making them a promising therapeutic approach ... murine model ...

Rise of the armoured CARs (and the drive toward solid tumour) Cell therapy researchers love their ... presented new data on how it’s using CAR-macrophages to navigate the TME in patients with ...

Studies have demonstrated that MSCs can alleviate skin fibrosis by inhibiting CCL2 production and reducing the recruitment of pathological macrophages; their paracrine effects can exert extensive ...

NK cells are emerging as a potentially safer and more convenient alternative to the current generation of CAR-T cell therapies ... to include a macrophage-based therapy for an undisclosed ...

Bristol Myers Squibb today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Breyanzi® (lisocabtagene maraleucel; ...

it’s not yet clear how sharing CARs between T cells might impact CAR-T therapy efficacy or influence the design of future synthetic receptors, experts told STAT. However, the work does reveal ...

Furthermore, adoptive macrophage and natural killer cell therapies hold promise for not only their ... including chimeric antigen receptor (CAR)-T-cell therapy, tumor-infiltrating lymphocyte (TIL) ...